Open Accessibility Menu

Coronavirus (COVID-19) Vaccine Update Click here to learn more.

For information about COVID-19 or to view additional resources, please click here.

Vaccinations in Pregnancy

Vaccinations can help protect you from certain infections and diseases that can harm you and your baby. The Tdap and influenza vaccines (flu shot) are recommended in pregnancy. Not all vaccines are safe to get during pregnancy, so you should speak to your provider or care team for more guidance.


• The Tdap vaccine protects you and your baby against contracting tetanus, diphtheria, and pertussis. It is recommended that you get the Tdap vaccine between 27 and 36 weeks of pregnancy.

• The flu shot protects you and your baby against contracting the flu. It is recommended that you get a flu shot every flu season, even when pregnant. Before getting a vaccination, talk to your provider or care team and let them know if you have any allergies or have ever had an allergic reaction to a vaccine. An allergic reaction is a bad reaction to something you eat, touch, or breathe in. Usually allergies result in itching, sneezing, a rash or hives, or trouble breathing.

For more information,

Common Vaccinations Recommendations during pregnancy:

  • Flu shot (influenza) - Yes, recommended (does not include the nasal spray)
  • Tdap (tetanus, diphtheria, and pertussis) - Yes, recommended
  • Hepatitis A - Talk to your provider or care team
  • Hepatitis B - Talk to your provider or care team
  • HPV (human papillomavirus) - Talk to your provider or care team
  • MMR (measles, mumps, rubella) - No, not recommended
  • Chickenpox (varicella) - No, not recommended
  • Shingles (zoster) - No, not recommended
Conveniently Located

Clinical Trials

  • This study is looking at the relationship between sleep and perinatal mood disorders such as depression and anxiety. Participants will wear a wrist monitor like a fit bit for 10 days to help researchers gain information into sleep patterns during pregnancy and postpartum and will answer questionnaires about their mood.
  • Preterm birth is one of the leading causes of neonatal morbidity and mortality. One of the most significant risk factors is a history of a prior spontaneous preterm birth. Intramuscular progesterone is the only FDA approved medication for the prevention of recurrent preterm birth. Vaginal progesterone is not FDA approved for the prevention of recurrent preterm birth, but has been found to beneficial. Given the presence of trials demonstrating efficacy for both intramuscular and vaginal progesterone in the prevention of recurrent preterm birth, but limited information one being more superior to the other, we are performing a trial comparing vaginal progesterone and intramuscular progesterone for the prevention of recurrent spontaneous preterm birth in women with a history of prior spontaneous preterm birth.
  • [This study is no longer recruiting.] The SONATA Study is an FDA-approved clinical study designed to establish the safety and effectiveness of a new, investigational device to reduce heavy menstrual bleeding caused by uterine fibroids. The device, called the SONATA System, targets fibroids rather than treatment or removing the entire uterus. If effective, this device will provide an alternative to hysterectomy that is: incision-free, preserves the uterus, does not require general anesthesia and is an outpatient procedure.
  • Women with twin pregnancy who have a dilated (open) cervix detected on physical exam before 24 weeks are at increased risk for delivering their babies preterm (before 37 weeks gestation). Prematurity is associated with many complications for the babies including respiratory (breathing) problems, bleeding inside of the brain (a form of stroke), increased risk of infection, kidney, temperature and feeding problems. The primary objective of this study is to determine if physical exam indicated cerclage use reduces the incidence of spontaneous PTB in asymptomatic women with twin gestations with cervical dilation diagnosed on pelvic exam before 24 weeks of gestation.
  • Tranexamic acid was shown to significantly reduce risk of mortality when given to women with diagnosed postpartum hemorrhage in the recent Lancet WOMAN Trial.* The purpose of this study is to determine the optimal dose for using tranexamic acid to prevent postpartum hemorrhage during routine cesarean section. Women undergoing cesarean section will be eligible and must not have a history of blood clots or a known clotting condition. *
  • In this study, we are developing non-invasive tools to identify early signs of abnormalities of the placental function using arterial spin labeling (ASL) based on fetal MRI. ASL is a particularly attractive method for early and safe monitoring during pregnancy given that ASL is completely non-invasive and does not require contrast agents or exposure to ionizing radiation. Our specific aim is to develop and validate placental perfusion imaging with substantially improved image quality and sensitivity to abnormalities.
  • This study is being performed at Children's National Health System. We are trying to understand how the normal fetus controls blood flow to the different parts of the body such as the lungs and brain. We will measure your baby's blood flow using the same ultrasound approach used by your obstetrician. We will test your baby's control of blood flow by measuring the responses to changes in your (the mom's), levels of oxygen and carbon dioxide. We will make these changes by asking you to breathe extra oxygen for short periods of time. If your obstetrician determines that your pregnancy is uncomplicated, you and your baby are eligible for this study.